We are live on ! Find out more
ENZ

Enzo Biochem, Inc.
ENZ

Delisted

ENZ was delisted on the 17th of April, 2025.

Back to rankings

39 hedge funds and large institutions have $23.1M invested in Enzo Biochem, Inc. in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

385% more call options, than puts

Call options by funds: $165K | Put options by funds: $34K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

17% less funds holding

Funds holding: 47 → 39 (-8)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

33% less capital invested

Capital invested by funds: $34.7M → $23.1M (-$11.5M)

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

Holders
39
Holders Change
-8
Holders Change %
-17.02%
% of All Funds
0.62%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
7
Reduced
9
Closed
11
Calls
$165K
Puts
$34K
Net Calls
+$131K
Net Calls Change
+$17K

Top Buyers

Rank Fund Capital Flow
1
PCM
Potomac Capital Management
New York
+$611K
2
SC
Shay Capital
New York
+$94.2K
3
Morgan Stanley
Morgan Stanley
New York
+$12.1K
4
TRCT
Tower Research Capital (TRC)
New York
+$8.36K
5
C
Covestor
United Kingdom
+$5.98K

Top Sellers

Rank Fund Capital Flow
1
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
California
-$1.81M
2
RAM
Roumell Asset Management
Maryland
-$1.25M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$639K
4
Renaissance Technologies
Renaissance Technologies
New York
-$224K
5
FLC
Fifth Lane Capital
Texas
-$156K
Name Holding Trade Value Shares
Change 		Change in
Stake
HFA
1
Harbert Fund Advisors
Alabama
$7.25M – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$3.58M -$224K -148,800 -6%
TCM
3
Tang Capital Management
California
$3.08M -$151K -100,000 -4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$2.42M – – –
PCM
5
Potomac Capital Management
New York
$2.04M +$611K +405,100 +39%
BlackRock
6
BlackRock
New York
$1.34M -$65K -43,085 -4%
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$1.18M -$639K -423,989 -33%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$473K +$424 +281 +0.1%
RC
9
RBF Capital
California
$351K – – –
BCM
10
Bridgeway Capital Management
Texas
$318K -$124K -82,299 -27%
State Street
11
State Street
Massachusetts
$234K – – –
Northern Trust
12
Northern Trust
Illinois
$146K -$601 -399 -0.4%
Assenagon Asset Management
13
Assenagon Asset Management
Luxembourg
$114K -$152K -100,665 -55%
Morgan Stanley
14
Morgan Stanley
New York
$106K +$12.1K +8,000 +12%
SC
15
Shay Capital
New York
$87.5K +$94.2K +62,500 New
Lazard Asset Management
16
Lazard Asset Management
New York
$70K – – –
T. Rowe Price Associates
17
T. Rowe Price Associates
Maryland
$63K – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$36.7K – – –
KCM
19
Kempner Capital Management
Texas
$36K – – –
SMA
20
Sage Mountain Advisors
Georgia
$32.7K – – –
SCA
21
Snowden Capital Advisors
New York
$30.1K -$1.81K -1,200 -5%
AWM
22
AE Wealth Management
Kansas
$28K – – –
TPA
23
Trivium Point Advisory
Connecticut
$26.3K – – –
RJT
24
Raymond James Trust
Florida
$23.8K – – –
SDAM
25
Shulman DeMeo Asset Management
New York
$21.7K – – –
1
2

ENZ Hedge Fund Activity: Q3 2023 in Review

39 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q3 2023, worth a combined $23.1M — down 33% from $34.7M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ENZ and 4 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 7 added.

The largest buyer was Potomac Capital Management, adding an estimated $611K. The largest seller was Fuller & Thaler Asset Management, exiting entirely with an estimated $1.81M sold.

  • 39 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q3 2023, down from 47 in Q2 2023.
  • Funds reported $23.1M of Enzo Biochem, Inc. stock for Q3 2023, down 33% quarter-over-quarter.
  • 4 funds opened new Enzo Biochem, Inc. positions in Q3 2023 and 11 closed out, a net change of -7 holders.
  • The largest Enzo Biochem, Inc. buyer in Q3 2023 was Potomac Capital Management, an estimated $611K added.
  • The largest Enzo Biochem, Inc. seller in Q3 2023 was Fuller & Thaler Asset Management, an estimated $1.81M sold.

Based on aggregated 13F filings for Q3 2023.